All In Biotech

Drug Trial Radar · NCT07427628

A Proof-of-concept Trial to EvaluAte the efficaCy and Safety Of Cell Therapy TRX103 in Patients With Active, Non-infectious Uveitis

A Proof-of-Concept Trial to EvaluAte the EfficaCy and Safety Of Cell Therapy TRX103 Administered Intravenously in Patients With Active, Non-infectious Intermediate, Posterior, and Pan-Uveitis - PEACOCX Study

Last checked: Nov 19, 2026Latest source record: Nov 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

18

Planned (sponsor's estimate)

Start

Mar 18, 2026

Primary completion

Dec 2028

Study completion Dec 2028

Sponsor

Lead sponsor
Quan Dong NguyenAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Feb 23, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this Phase 1, first in uveitis open-label study is to assess the safety and tolerability of TRX-103 in patients with non infectious uveitis (NIU). It is anticipated that up to 18 Subjects will be enrolled during a 18-24 month enrollment period. TRX-103 will be infused one time.

Conditions

  • Non Infectious Uveitis

Interventions

  • TRX103Biological

    TRX103 infusion via peripheral line

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of Treatment emergent Adverse events and Serious Adverse events at week 52Time frame: Up to a year
  2. Incidence of infections, either bacterial, fungal or viral at week 52Time frame: Upto 1 year
  3. Negative Replication Competent Lentivirus (RCL) at approximately 3-months, 6-months, and 12-months.Time frame: At 3-month, 6-month, and 1-year.

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Byers Eye Institute

    Palo Alto, California · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.